Published in Am J Nephrol on January 30, 2010
Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice. Ther Adv Cardiovasc Dis (2014) 0.77
Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats. Kidney Blood Press Res (2014) 0.75
Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl) (2016) 0.75
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature (1987) 8.28
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell (1996) 7.69
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature (1987) 6.45
Cardiac plasticity. N Engl J Med (2008) 6.29
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 5.12
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell (1994) 3.74
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int (1995) 3.70
Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A (1985) 3.62
Ki67 protein: the immaculate deception? Histopathology (2002) 3.61
Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science (1993) 3.28
Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci U S A (1987) 3.05
Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res (2004) 2.92
Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis (1999) 2.65
Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int (1989) 2.55
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A (1994) 1.95
Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med (2008) 1.91
Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase mRNA levels by growth factors. J Biol Chem (1988) 1.70
Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol (1993) 1.66
Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development. Eur Heart J (1999) 1.60
Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial (2003) 1.59
Cell-specific responses to loss of cyclin-dependent kinases. Oncogene (2007) 1.41
Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem (2000) 1.39
Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol (1998) 1.37
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance. Kidney Int (1988) 1.27
The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci (2004) 1.26
End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes. Circ Res (1994) 1.22
Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KIP1 knockout mice. Circ Res (1999) 1.20
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int (2004) 1.16
BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem (2001) 1.10
Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol (1998) 1.09
Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res (2002) 1.06
Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail (2001) 1.05
BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene (2001) 1.03
A cyclin D2-Rb pathway regulates cardiac myocyte size and RNA polymerase III after biomechanical stress in adult myocardium. Circ Res (2008) 0.98
Morphology of the heart and arteries in renal failure. Kidney Int Suppl (2003) 0.98
Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol (1997) 0.97
Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol (1993) 0.97
Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. Mol Cell Biol (2007) 0.95
Cardiac remodelling in experimental renal failure--an immunohistochemical study. Nephrol Dial Transplant (1998) 0.95
Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transplant (1995) 0.94
Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Exp Cell Res (2004) 0.94
Cellular mechanisms of normal growth in the mammalian heart. I. Qualitative and quantitative features of ventricular architecture in the dog from birth to five months of age. Circ Res (1979) 0.91
Measuring cell proliferation. Arch Pathol Lab Med (1991) 0.89
Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med (2005) 0.85
Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest (2009) 0.85
Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol (2009) 0.84
Parathyroid hormone-related protein antagonizes the action of parathyroid hormone on adult cardiomyocytes. J Biol Chem (1996) 0.84
Rat parathyroid hormone 1-34 signals through the MEK/ERK pathway to induce cardiac hypertrophy. J Int Med Res (2008) 0.81
Vitamin D. Am J Physiol Renal Physiol (2005) 4.81
Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol (2009) 2.29
Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int (2005) 2.15
Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens (2005) 1.86
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol (2010) 1.78
Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol (2007) 1.66
Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. Nephrol Dial Transplant (2012) 1.52
Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant (2008) 1.43
Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int (2003) 1.41
Maternal Nanos represses hid/skl-dependent apoptosis to maintain the germ line in Drosophila embryos. Proc Natl Acad Sci U S A (2007) 1.34
Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int (2011) 1.27
FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol (2006) 1.24
Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med (2008) 1.20
Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat Clin Pract Endocrinol Metab (2007) 1.14
Accumulation of 8-oxoguanine in the cellular DNA and the alteration of the OGG1 expression during ischemia-reperfusion injury in the rat kidney. DNA Repair (Amst) (2003) 1.14
Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med (2002) 1.11
Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int (2003) 1.11
1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem (2002) 1.10
Clinical consequences and management of hypomagnesemia. J Am Soc Nephrol (2008) 1.10
The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol (2002) 1.10
Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol (2011) 1.08
Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol (2008) 1.00
EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol (2008) 0.97
Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab (2005) 0.96
The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res (2012) 0.94
Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant (2002) 0.94
A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol (2005) 0.94
Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy. Nephrol Dial Transplant (2004) 0.94
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis (2002) 0.93
Genetically encoded system to track histone modification in vivo. Sci Rep (2013) 0.93
Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int (2002) 0.92
Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol (2005) 0.92
Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol (2010) 0.92
Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol (2004) 0.92
Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int (2003) 0.92
Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol (2003) 0.91
Elastin degradation accelerates phosphate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int (2009) 0.91
Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol (2010) 0.90
Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial (2010) 0.90
Lupus nephritis associated with positive MPO-ANCA in a patient with underlying autoimmune hemolytic anemia. Clin Exp Nephrol (2008) 0.90
Relation of serum fetuin-A levels to coronary artery calcium in African-American patients on chronic hemodialysis. Am J Cardiol (2008) 0.89
Slowly progressive and painless thoracic aortic dissection presenting with a persistent Fever in an elderly patient: the usefulness of combined measurement of biochemical parameters. Case Rep Med (2013) 0.89
Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol (2010) 0.89
FGF23 and PTH--double agents at the heart of CKD. Nephrol Dial Transplant (2012) 0.88
Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion. J Cell Biochem (2005) 0.87
Intracranial dilative arteriopathy is associated with chronic kidney disease and small vessel diseases in the elderly. J Stroke Cerebrovasc Dis (2009) 0.87
Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int (2013) 0.86
Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol (2004) 0.86
Destabilization of parathyroid hormone mRNA by extracellular Ca2+ and the calcimimetic R-568 in parathyroid cells: role of cytosolic Ca and requirement for gene transcription. J Mol Endocrinol (2008) 0.86
Vitamin D receptor and analogs. Semin Nephrol (2004) 0.86
Occurrence and clinicotopographical correlates of brainstem infarction in patients with diabetes mellitus. J Stroke Cerebrovasc Dis (2011) 0.85
Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. Nefrologia (2013) 0.85
Deep white matter hyperintensities, decreased serum low-density lipoprotein, and dilative large arteriopathy. J Stroke Cerebrovasc Dis (2010) 0.84
Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol (2009) 0.84
Characterization of the isoforms of MOVO zinc finger protein, a mouse homologue of Drosophila Ovo, as transcription factors. Gene (2004) 0.84
Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol (2009) 0.84
Calcium-sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells. J Bone Miner Res (2009) 0.83
Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol (2011) 0.83
Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo. Biochem Pharmacol (2004) 0.83
Expression of synaptopodin and GLEPP1 as markers of steroid responsiveness in primary focal segmental glomerulosclerosis. Life Sci (2006) 0.83
Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism. J Am Soc Nephrol (2008) 0.83
Maternal RNAs encoding transcription factors for germline-specific gene expression in Drosophila embryos. Int J Dev Biol (2008) 0.83
Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant (2002) 0.82
Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant (2003) 0.82
Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2010) 0.81
Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol Dial Transplant (2013) 0.80
Involvement of matrix metalloproteinase-2 in the development of medial layer vascular calcification in uremic rats. Ther Apher Dial (2011) 0.79
Biocompatible characteristics of high-performance membranes. Contrib Nephrol (2011) 0.79
Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int (2002) 0.79
Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clin Exp Nephrol (2011) 0.78
[Renal failure and vitamin D]. Clin Calcium (2002) 0.78
Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin Exp Nephrol (2003) 0.78
The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant (2005) 0.78
Parathyroid cells cultured in collagen matrix retain calcium responsiveness: importance of three-dimensional tissue architecture. J Bone Miner Res (2004) 0.78
50 years of research and discovery in chronic kidney disease and mineral & bone disorder: the central role of phosphate. Kidney Int Suppl (2011) 0.78
Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res (2002) 0.78
Dilative arterial remodeling of the brain with different effects on the anterior and posterior circulation: an MRI study. J Neurol Sci (2009) 0.78
A case report of syndrome of inappropriate secretion of antidiuretic hormone with marked edema due to administration of hypertonic saline. Ther Apher Dial (2007) 0.78
Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients. Clin J Am Soc Nephrol (2010) 0.78
1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol (2004) 0.78
The vitamin D analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) vitamin D(3) (Eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int (2011) 0.77
Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis. Ther Apher Dial (2014) 0.77
The role of the serum vitamin D binding protein in the actions of the vitamin D analog eldecalcitol (ED-71) on bone and mineral metabolism. Calcif Tissue Int (2013) 0.77
Relationship between residual renal function and serum fibroblast growth factor 23 in patients on peritoneal dialysis. Ther Apher Dial (2014) 0.77
Ultrapure dialysate influences serum myeloperoxidase levels and lipid metabolism. Blood Purif (2009) 0.77
Does cinacalcet improve the prognosis of dialysis patients? Ther Apher Dial (2009) 0.77
Mechanistic analysis for time-dependent effects of cinacalcet on serum calcium, phosphorus, and parathyroid hormone levels in 5/6 nephrectomized rats. Physiol Rep (2013) 0.76
Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial (2004) 0.76
Molecular basis of parathyroid hyperplasia. J Ren Nutr (2007) 0.76